96823 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
Compositions and methods for activating innate and allergic immunity
#302DNAs AND PROTEINS OR PEPTIDES SPECIFIC TO BACTERIA OF THE SPECIES NEISSERIA MENINGITIDIS, PROCESS FOR OBTAINING THEM AND THEIR BIOLOGICAL USES
#303Gonococcal proteins and nucleic acids
#304Regimens for immunisation with meningococcal conjugates
#305PHARMACEUTICAL COMPOSITION CONTAINING THE NMB0938 PROTEIN
#306Domains And Epitopes Of Meningococcal Protein NMB1870
#307Surface antigen
#308REPLIKIN PEPTIDES IN RAPID REPLICATION OF GLIOMA CELLS AND IN INFLUENZA EPIDEMICS
#309Magnetic resonance contrast medium containing an iron-binding protein
#310antigens and compositions
#311Polypeptide carrier protein
#312VACCINES AND THEIR USE
#313Lipidating sequences and use thereof for producing lipidated proteins in
#314PHARMACEUTICAL COMPOSITIONS CONTAINING PROTEIN NMA0939
#315Antibiotic compositions and related screening methods
#316Novel immunogenic compositions for the prevention and treatment of meningococcal disease
#317Liposome-mediated ligation
#318Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#319Capsular polysaccharide solubilisation and combination vaccines
#320Capsular polysaccharide solubilisation and combination vaccines
#321Capsular polysaccharide solubilisation and combination vaccines
#322Capsular polysaccharide solubilisation and combination vaccines
#323Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial Adhesin
#324Vaccine Composition
#325Nucleic acids and polypeptides specific for pathogenic strains of the genus
#326Multicomponent meningococcal vaccine
#327REPLIKIN PEPTIDES AND ANTIBODIES THEREFORE
#328Capsular polysaccharide solubilisation and combination vaccines
#329Capsular polysaccharide solubilisation and combination vaccines
#330Capsular polysaccharides solubilisation and combination vaccines
#331Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine
#332BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis
#333Modified surface antigen
#334Modified surface antigen
#335USE OF PENICILLIN-BINDING PROTEINS OR POLYNUCLEOTIDES OR ANTIBODIES THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS
#336Glycolipopeptide antibodies
#337Replikins and methods of identifying replikin-containing sequences
#338GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by
#339Virulence genes, proteins, and their use
#340Vaccine Composition
#341Compositions and methods to prevent cancer with cupredoxins
#342Polynucleotides and polypeptides BASB033 from neisseria meningitidis and their uses
#343Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
#344Chimeric Tbp-toxin proteins as mucosal adjuvants for vaccination against neisseriae
#345Nucleic acid molecules encoding proteins which impart the adhesion of cells to human cells
#346Lactoferrin cleavage of neisserial proteins
#347Immunogenic Compositions Comprising Multiple Gonococcal Antigens
#348Compositions and methods to prevent cancer with cupredoxins
#349Vaccines Against Neisseria Meningitidis
#350Conserved Neisserial antigens
#351Neisserial antigens
#352PROTEINASE K RESISTANT SURFACE PROTEIN OF NEISSERIA MENINGITIDIS
#353Proteinase K resistant surface protein of
#354Proteinase K resistant surface protein of
#355Surface protein of Neisseria bacteria
#356PROTEINASE K RESISTANT SURFACE PROTEIN OF NEISSERIA MENINGITIDIS
#357Proteinase K resistant surface protein of
#358PROTEINASE K RESISTANT SURFACE PROTEIN OF NEISSERIA MENINGITIDIS
#359Polypeptides and Polynucleotides "BASB040" From Neisseria Meningitidis and Vaccine Comprising Said Polypeptides and Polynucleotides
#360High-cell density fed-batch fermentation process for producing recombinant protein
#361Regimens for immunisation with meningococcal conjugates
#362Method for Refolding Neisserial Nspa Protein
#363Method for producing α-1, 6-branched α-1, 4-glucans from sucrose
#364Method for producing alpha-1, 6-branched alpha-1, 4-glucans from sucrose
#365Method for producing alpha-1, 6-branched alpha-1, 4-glucans from sucrose
#366Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
#367Identification of Antigenically Important Neisseria Antigens by Screening Insertional Mutant Libraries with Antiserum
#368Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
#369MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE, VACCINE COMPRISING THE SAME AND USE THEREOF
#370Combination neisserial compositions
#371Neisseria genomic sequences and methods of their use
#372Protein NMB1125 and use thereof in pharmaceutical formulations
#373Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
#374Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
#375Antibody fragments specific for human carcinoembryonic antigen (CEA)
#376Method of antigen incorporation into neisseria bacterial outer membrane vesicles and resulting vaccine formulations
#377Methods for increasing neisseria protein expression and compositions thereof
#378Protein nmb0928 and use thereof in pharmaceutical formulations
#379Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
#380Proteinase K resistant surface protein of
#381DNA and proteins or peptides specific of bacteria of the species, methods for obtaining them and biological applications thereof
#382Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
#383Omp85 proteins of and , compositions containing same and methods of use thereof
#384Ultrafiltration for preparing outer membrane vesicles
#385Novel immunogenic compositions for the prevention and treatment of meningococcal disease
#386DNA and proteins or peptides specific of bacteria of the Neisseria meningitidis species, methods for obtaining them and biological applications thereof
#387Injectable vaccines against multiple meningococcal serogroups
#388Novel immunogenic compositions for the prevention and treatment of meningococcal disease
#389Novel immunogenic compositions for the prevention and treatment of meningococcal disease
#390Transferrin-binding proteins from
#391Unexpected surface proteins in meningococcus
#392Antigenic neisserial peptides
#393Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#394Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
#395Outer membrane vesicles and uses thereof
#396Neisseria meningitidis antigens and compositions
#397Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
#398Pharmaceutical liposomal compositions
#399Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics
#400Polyepitope carrier protein
#401Mutant forms of meningococcal ADP-ribosylating toxin
#402Immunogenic compositions for the prevention and treatment of meningococcal disease
#403Multiple variants of meningococcal protein nmb1870
#404Neisserial vaccine compositions comprising a combination of antigens
#40585kDa neisserial antigen
#406Vaccine composition
#407Vaccine composition
#408Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
#409Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
#410Bacterial outer memberane vesicles
#411Polysaccharide and glycoconjugate vaccines
#412Cupredoxin derived transport agents and methods of use thereof
#413Mutant protein and refolding method
#414Vaccine composition
#415DNA and proteins or peptides specific of the Neisseria meningitidis species bacteria, method for obtaining them and their biological applications
#416Vaccine composition
#417ADP-ribosylating bacterial toxins
#418Hybrid expression of neisserial proteins
#419Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-
#420inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
#421Means for identifying neisseria meningitidis-specific genes
#422Methods for isolating molecular mimetics of unique serogroup B epitopes
#423Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
#424System and method for identifying complex patterns of amino acids
#425Meningococcal antigens
#426Surface protein of bacteria
#427Polynucleotides and polypeptides BASB033 from Neisseria meningitidis and their uses
#428Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
#429Isolated FrpB nucleic acid molecule and vaccine
#430Gonococcal proteins and nucleic acids
#431Combination Neisserial compositions
#432Meningococcus adhesins nada, app and orf 40
#433Hybrid and tandem expression of neisserial proteins
#434genomic sequences and methods of their use
#435Neisserial vaccine compositions and methods
#436Specific antibody fragments for the human carcinoembryonic antigen (cea)
#437Neisseria spp. polypeptide, nucleic acid sequence and uses thereof
#438Gene expression during meningococcus adhesion
#439Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells
#440Neisseria mutants, lipooligosaccharides and immunogenic compositions
#441Capsular polysaccharide solubilisation and combination vaccines
#442compounds and anti-infection applications thereof
#443Neisseria meningitidis antigen
#444Omp85 proteins of and , compositions containing same and methods of use thereof
#445Surface antigen
#446Nucleic acids and polypeptides specific for pathogenic strains of the genus